After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Alkermes plc is $5.74B. A total of 1.42 million shares were traded on the day, compared to an average of 1.69M shares.
Insider Activity
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ALKS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, Parisi Samuel Joseph sold 1,938 shares of ALKS for 34.00 per share on Feb 28 ’25. After the transaction, the VP, Finance (Interim PAO) now owns 7,717 company shares. In a previous transaction on Feb 25 ’25, Parisi Samuel Joseph sold 3,743 shares at 35.26 per share. ALKS shares that VP, Finance (Interim PAO) owns now total 7,717.
Among the insiders who sold shares, Parisi Samuel Joseph disposed of 1,327 shares on Feb 20 ’25 at a per-share price of $35.69. This resulted in the VP, Finance (Interim PAO) holding 7,717 shares of ALKS after the transaction. In another insider transaction, Hopkinson Craig C. sold 204,921 shares at $32.78 per share on Feb 12 ’25. Company shares held by the EVP R&D, Chief Medical Officer now total 57,875.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ALKS in the last 3 months, the mean price target is $38.54 with high estimates of $46.00 and low estimates of $30.00. In terms of 52-week highs and lows, ALKS has a high of $36.45 and a low of $22.90.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ALKS’s latest balance sheet shows that the firm has $536.31M in Cash & Short Term Investments as of fiscal 2021. There were $416.21M in debt and $471.29M in liabilities at the time. Its Book Value Per Share was $9.03, while its Total Shareholder’s Equity was $1.11B.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALKS is Buy with a score of 4.20.
